The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.

Compounds according to Formula I: ##STR00001##
or a pharmaceutically acceptable salt wherein: A.sub.1 is NR.sub.1 or CR.sub.1, with R.sub.1 herein; the cyclopropyl moiety with one or more methyl and one or more F; A.sub.2-A.sub.5 are N or CR.sub.2-CR.sub.5, with no more than two of the four positions A in A.sub.2-A.sub.5 can be simultaneously N; R.sub.2-R.sub.5 are described; R.sub.6 and R.sub.7 are independently H, F, methyl, ethyl, hydroxyl or methoxy or R.sub.6 and R.sub.7 together is carbonyl, all alkyl groups, if substituted with one or more F; R.sub.8 is H or C(1-6)alkyl; A.sub.9-A.sub.12 are N or CR.sub.9-CR.sub.12, with no more than two of the four positions A in A.sub.9-A.sub.12 can be simultaneously N; R.sub.9-R.sub.12 herein; R.sub.13 and R.sub.14 herein; or R.sub.13 and R.sub.14 fused forming a ring having 5 to 7 atoms by joining R.sub.13 being C(1-6)alkyl or C(2-6)alkenyl. The ROR compounds can treat ROR mediated diseases.

Compounds according to Formula I: ##STR00001##
or a pharmaceutically acceptable salt wherein: A.sub.1 is NR.sub.1 or CR.sub.1, with R.sub.1 herein; the cyclopropyl moiety with one or more methyl and one or more F; A.sub.2-A.sub.5 are N or CR.sub.2-CR.sub.5, with no more than two of the four positions A in A.sub.2-A.sub.5 can be simultaneously N; R.sub.2-R.sub.5 are described; R.sub.6 and R.sub.7 are independently H, F, methyl, ethyl, hydroxyl or methoxy or R.sub.6 and R.sub.7 together is carbonyl, all alkyl groups, if substituted with one or more F; R.sub.8 is H or C(1-6)alkyl; A.sub.9-A.sub.12 are N or CR.sub.9-CR.sub.12, with no more than two of the four positions A in A.sub.9-A.sub.12 can be simultaneously N; R.sub.9-R.sub.12 herein; R.sub.13 and R.sub.14 herein; or R.sub.13 and R.sub.14 fused forming a ring having 5 to 7 atoms by joining R.sub.13 being C(1-6)alkyl or C(2-6)alkenyl. The ROR compounds can treat ROR mediated diseases.

A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.

Provided herein are compounds of formula I: ##STR00001##
and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various LSD1-mediated disorders.

Provided herein are compounds of formula I: ##STR00001##
and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various LSD1-mediated disorders.

The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I)-(VIII) and by Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70). These necrostatins are shown to inhibit TNF- induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring necrostatins. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I)-(VIII) and by Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70). These necrostatins are shown to inhibit TNF- induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring necrostatins. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

A method of reducing color in an alkanolamine is described. The method includes contacting the alkanolamine with a color-reducing amount of a borane complex effective to provide a color-reduced alkanolamine composition having a Platinum-Cobalt Color Value, according to Test Method ASTM D1209, of less than 50.

A novel compound for a capping layer, and an organic light emitting device containing the same are disclosed. The compound for a capping layer is represented by Formula 1 below:

##STR00001##